Cargando…
T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease
INTRODUCTION: The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. METHODS: T2 Protect AD (T2), a phase 2 randomized placebo‐controlled trial of trori...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919121/ https://www.ncbi.nlm.nih.gov/pubmed/35310528 http://dx.doi.org/10.1002/trc2.12265 |